Temporal Concept – Page 22

Biopharmaceutical Manufacturing and Emerging Trends in 2024: A Global Outlook

9 months ago talkbio0Tagged 2024, Biopharmaceutical manufacturing, Biosimilars, Biotechnology, Cells, Drug Discovery, gene therapy, innovations, Precision Medicine, trends qualifier

Biopharmaceutical manufacturing, 2024 trends, personalized medicine, AI-driven drug discovery, biosimilars, cell and gene therapies, biotechnology innovations.

Narsoplimab Demonstrates Significant Survival Benefit in Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

9 months ago talkbio0Tagged disease treatment, Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy, HSCT-TMA, Improvement, Infrequent, Inhibitor, Lectin, MASP2 protein, human, narsoplimab, Overall Survival, Psychological inhibition

Narsoplimab, Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA), Lectin Pathway Inhibition, MASP-2 Inhibitor, Rare Disease Treatment, Overall Survival Improvement

Roche’s Parkinson’s Drug Fails Second Mid-Stage Trial, Yet Shows Promising Trends

9 months ago talkbio0Tagged Clinical Trials, exploration, Failure (biologic function), Parkinson 's disease, Prasinezumab, Roche (company), trends qualifier

Roche, Parkinson’s disease, prasinezumab, clinical trial failure, promising trends, further exploration

Regeneron’s EYLEA HD Succeeds in Phase 3 Trial for Retinal Vein Occlusion, Paving Way for 2025 FDA Submission

9 months ago talkbio0Tagged aflibercept, dosing, Extension, Eylea, Hodgkin Disease, Interval, Phase 3 QUASAR trial, Regeneron, Retinal Vein Occlusion, Submission, United States Food and Drug Administration

EYLEA HD, Aflibercept, Retinal Vein Occlusion (RVO), Phase 3 QUASAR Trial, Extended Dosing Intervals, FDA Submission 2025, Regeneron Pharmaceuticals

Viridian’s Veligrotug Demonstrates Efficacy in Second Pivotal Study for Thyroid Eye Disease

9 months ago talkbio0Tagged Antibodies, Clinical Trials, IGF1R protein, human, Phase 3, THRIVE-2, Thyroid associated opthalmopathies, Veligrotug, Viridian

Thyroid Eye Disease, Veligrotug, Viridian Therapeutics, Phase 3 Clinical Trial, THRIVE-2, IGF-1R Antibody

Reviva’s Brilaroxazine Demonstrates Efficacy and Safety in Long-Term Schizophrenia Treatment

9 months ago talkbio0Tagged Ability to perform cognitive activity, Antipsychotic Agents, Brilaroxazine, Effectiveness, Long-term, Negative, Safety, Schizophrenia, Symptoms aspect

Brilaroxazine, Schizophrenia treatment, Antipsychotic medication, Efficacy and safety, Long-term treatment, Negative symptoms, Cognitive functioning

Advancements in ctDNA Testing for Early Detection of Breast Cancer Recurrence

9 months ago talkbio0Tagged Breast Cancer Recurrence, Circulating, ctDNA, Detection, Liquid Biopsy, Molecular residual disease, Whole Genome Sequencing

ctDNA (circulating tumor DNA), Breast Cancer Recurrence, Early Detection, Liquid Biopsy, Whole Genome Sequencing, Molecular Residual Disease

Pfizer’s IBRANCE Demonstrates Significant Efficacy in HR+, HER2+ Metastatic Breast Cancer

9 months ago talkbio0Tagged Anti-HER2 therapy, Carcinoma breast stage IV, erbB-2 Receptor, Hormone Therapy, Ibrance, palbociclib, Phase 3, Progression-Free Survival, standard-of-care

IBRANCE (palbociclib), HR+/ HER2+ metastatic breast cancer, Phase 3 PATINA trial, Progression-free survival (PFS), Standard-of-care therapies, Anti-HER2 therapy, Endocrine therapy